Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Aug;93(2):229–236. doi: 10.1111/j.1365-2249.1993.tb07971.x

Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.

K Yoneda 1, T Osaki 1, T Yamamoto 1, E Ueta 1
PMCID: PMC1554840  PMID: 8348749

Abstract

Roles of monocytes and cytokines were investigated on LAK induction from T and NK cells. Monocytes augmented more T-LAK induction than did NK-LAK. Expression of IL-1 beta, TNF-alpha and interferon-gamma (IFN-gamma)-mRNA and their cytokine production were superior in NK cells compared with T cells in parallel with their LAK activities. An increase of TNF-alpha, IL-1 beta and IFN-gamma production was induced by co-culturing NK or T cells with autologous monocytes. The augmentation of T cell cytokine production and T-LAK activity by monocytes was more prominent than that of NK cells. TNF-alpha and IL-1 beta were generated 24 h after IL-2 stimulation, and these cytokines were able to almost substitute for monocytes in LAK induction. Conversely, LAK induction was almost completely suppressed by both anti-IL-1 beta and anti-TNF-alpha antibodies, if they were added within 24 h after the start of the LAK induction. IFN-gamma, which was produced at a later stage, scarcely affected LAK induction in spite of the cooperation with TNF-alpha. The results obtained indicate conclusively that the superiority of NK-LAK depends on their superior productivity of both IL-1 beta and TNF-alpha, and that the up-regulation of LAK induction by monocytes is largely due to the enhanced generation of both cytokines.

Full text

PDF
229

Images in this article

233Fig. 3
on p.233

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe S., Gatanaga T., Yamazaki M., Soma G., Mizuno D. Purification of rabbit tumor necrosis factor. FEBS Lett. 1985 Jan 28;180(2):203–206. doi: 10.1016/0014-5793(85)81071-1. [DOI] [PubMed] [Google Scholar]
  2. Blay J. Y., Bertoglio J., Fradelizi D., Chouaib S. Functional interactions of IL2 and TNF in the differentiation of LGL into LAK effectors. Int J Cancer. 1989 Oct 15;44(4):598–604. doi: 10.1002/ijc.2910440407. [DOI] [PubMed] [Google Scholar]
  3. Boccoli G., Masciulli R., Ruggeri E. M., Carlini P., Giannella G., Montesoro E., Mastroberardino G., Isacchi G., Testa U., Calabresi F. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res. 1990 Sep 15;50(18):5795–5800. [PubMed] [Google Scholar]
  4. Chouaib S., Bertoglio J., Blay J. Y., Marchiol-Fournigault C., Fradelizi D. Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6875–6879. doi: 10.1073/pnas.85.18.6875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Crump W. L., 3rd, Owen-Schaub L. B., Grimm E. A. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res. 1989 Jan 1;49(1):149–153. [PubMed] [Google Scholar]
  6. Damle N. K., Doyle L. V., Bradley E. C. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol. 1986 Nov 1;137(9):2814–2822. [PubMed] [Google Scholar]
  7. Farace F., Mathiot C., Brandely M., Tursz T., Dorval T., Pouillart P., Triebel F., Hercend T., Fridman W. H. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma. Clin Exp Immunol. 1990 Nov;82(2):194–199. doi: 10.1111/j.1365-2249.1990.tb05426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  9. Fujiwara T., Grimm E. A. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction. J Immunol. 1992 May 1;148(9):2941–2946. [PubMed] [Google Scholar]
  10. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  11. Huberman M., Bering H., Fallon B., Tessitore J., Sonnenborn H., Paul S., Zeffren J., Levitt D., Groopman J. A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors. Cancer. 1991 Oct 15;68(8):1708–1713. doi: 10.1002/1097-0142(19911015)68:8<1708::aid-cncr2820680810>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  12. Jemma C., Cignetti A., Geuna M., Caretto P., Vai S., Forni G. In vitro and in vivo comparison of the activity of human lymphokine-activated killer (LAK) cells and adherent LAK cells. J Immunother (1991) 1991 Jun;10(3):189–199. doi: 10.1097/00002371-199106000-00005. [DOI] [PubMed] [Google Scholar]
  13. Lachman L. B., Shih L. C., Brown D. C. Interleukin 1 from human leukemic monocytes. Methods Enzymol. 1985;116:467–479. doi: 10.1016/s0076-6879(85)16038-6. [DOI] [PubMed] [Google Scholar]
  14. Lee J. C., Truneh A., Smith M. F., Jr, Tsang K. Y. Induction of interleukin 2 receptor (TAC) by tumor necrosis factor in YT cells. J Immunol. 1987 Sep 15;139(6):1935–1938. [PubMed] [Google Scholar]
  15. Lowenthal J. W., Cerottini J. C., MacDonald H. R. Interleukin 1-dependent induction of both interleukin 2 secretion and interleukin 2 receptor expression by thymoma cells. J Immunol. 1986 Aug 15;137(4):1226–1231. [PubMed] [Google Scholar]
  16. Malkovský M., Loveland B., North M., Asherson G. L., Gao L., Ward P., Fiers W. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature. 1987 Jan 15;325(6101):262–265. doi: 10.1038/325262a0. [DOI] [PubMed] [Google Scholar]
  17. Mittelman A., Puccio C., Ahmed T., Zeffren J., Choudhury A., Arlin Z. A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma. Cancer. 1991 Oct 15;68(8):1699–1702. doi: 10.1002/1097-0142(19911015)68:8<1699::aid-cncr2820680808>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  18. Nii A., Sone S., Utsugi T., Yanagawa H., Ogura T. Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state. Int J Cancer. 1988 Jan 15;41(1):33–40. doi: 10.1002/ijc.2910410108. [DOI] [PubMed] [Google Scholar]
  19. Owen-Schaub L. B., Crump W. L., 3rd, Morin G. I., Grimm E. A. Regulation of lymphocyte tumor necrosis factor receptors by IL-2. J Immunol. 1989 Oct 1;143(7):2236–2241. [PubMed] [Google Scholar]
  20. Owen-Schaub L. B., Gutterman J. U., Grimm E. A. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 1988 Feb 15;48(4):788–792. [PubMed] [Google Scholar]
  21. Pross H. F., Baines M. G., Rubin P., Shragge P., Patterson M. S. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981 Jan;1(1):51–63. doi: 10.1007/BF00915477. [DOI] [PubMed] [Google Scholar]
  22. Rivoltini L., Gambacorti-Passerini C., Squadrelli-Saraceno M., Grosso M. I., Cantù G., Molinari R., Orazi A., Parmiani G. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res. 1990 Sep 1;50(17):5551–5557. [PubMed] [Google Scholar]
  23. Sawada H., Abo T., Sugawara S., Kumagai K. Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes. J Immunol. 1988 May 15;140(10):3668–3673. [PubMed] [Google Scholar]
  24. Silvennoinen O., Vakkila J., Hurme M. Accessory cells, dendritic cells, or monocytes, are required for the lymphokine-activated killer cell induction from resting T cell but not from natural killer cell precursors. J Immunol. 1988 Aug 15;141(4):1404–1409. [PubMed] [Google Scholar]
  25. Singh S. M., Sone S., Inamura N., Ogura T. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes. Int J Cancer. 1989 Jul 15;44(1):170–176. doi: 10.1002/ijc.2910440130. [DOI] [PubMed] [Google Scholar]
  26. Sone S., Kunishige E., Fawzy F., Yanagawa H., Nii A., Maeda K., Atagi S., Heike Y., Nishioka Y., Mizuno K. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients. Jpn J Cancer Res. 1991 Jun;82(6):716–723. doi: 10.1111/j.1349-7006.1991.tb01908.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sone S., Utsugi T., Nii A., Ogura T. Effects of human alveolar macrophages on the induction of lymphokine (IL 2)-activated killer cells. J Immunol. 1987 Jul 1;139(1):29–34. [PubMed] [Google Scholar]
  28. Tsujimoto M., Vilcek J. Tumor necrosis factor receptors in HeLa cells and their regulation by interferon-gamma. J Biol Chem. 1986 Apr 25;261(12):5384–5388. [PubMed] [Google Scholar]
  29. Tsujimoto M., Vilcek J. Tumor necrosis factor-induced downregulation of its receptors in HeLa cells. J Biochem. 1987 Dec;102(6):1571–1577. doi: 10.1093/oxfordjournals.jbchem.a122206. [DOI] [PubMed] [Google Scholar]
  30. Warner S. J., Auger K. R., Libby P. Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol. 1987 Sep 15;139(6):1911–1917. [PubMed] [Google Scholar]
  31. Watanabe N., Niitsu Y., Yamauchi N., Umeno H., Sone H., Neda H., Urushizaki I. Antitumor synergism between recombinant human tumor necrosis factor and recombinant human interferon-r. J Biol Response Mod. 1988 Feb;7(1):24–31. [PubMed] [Google Scholar]
  32. Weiner L. M., Padavic-Shaller K., Kitson J., Watts P., Krigel R. L., Litwin S. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon. Cancer Res. 1991 Aug 1;51(15):3910–3918. [PubMed] [Google Scholar]
  33. Yoneda K., Yamamoto T., Ueta E., Osaki T. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients. J Clin Immunol. 1992 Jul;12(4):289–299. doi: 10.1007/BF00918153. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES